会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Indolamid derivatives which possess glycogenphosphorylase inhibitory activity
    • 具有糖原磷酸化酶抑制活性的吲哚衍生物衍生物
    • US07138415B2
    • 2006-11-21
    • US10506554
    • 2003-03-04
    • Paul Robert Owen WhittamoreStuart Norman Lile BennettIain Simpson
    • Paul Robert Owen WhittamoreStuart Norman Lile BennettIain Simpson
    • A61K31/454A61K31/41A61K31/404C07D401/12C07D257/04C07D209/30
    • C07D401/12C07D209/42C07D403/12C07D409/12C07D413/12
    • Heterocyclic amides of formula (1) wherein: is a single or double bond; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; r is 1 or 2; Y is —NR2R3 or —OR3; R2 and R3 are selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8 groups); R4 is selected from for example hydrogen, halo, nitro, cyano, hydroxy, C1-4alkyl, and C1-4alkanoyl; R8 is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R9), —NHC(O)R9, (R9)(R10)N— and —COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.
    • 式(1)的杂环酰胺其中:是单键或双键; A是亚苯基或亚杂芳基; m为0,1或2; n为0,1或2; R 1选自例如卤素,硝基,氰基,羟基,羧基; r为1或2; Y是-NR 2 R 3或-OR 3; R 2和R 3选自例如氢,羟基,芳基,杂环基和C 1-4 - 烷基(任选地被1或 2个R 8个基团); R 4选自例如氢,卤素,硝基,氰基,羟基,C 1-4烷基和C 1-4烷酰基 ; R 8选自例如羟基,-COCOOR 9,-C(O)N(R 9)(R 9) ),-NHC(O)R 9,(R 9)(R 10)N - 和-COOR 9 ; R 9和R 10选自例如氢,羟基,C 1-4烷基(任选被1或2个R SUP取代 > 13 ); R 13选自羟基,卤素,三卤代甲基和C 1-4烷氧基; 或其药学上可接受的盐或前体药物; 具有糖原磷酸化酶抑制活性,因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。 描述了制备所述杂环酰胺衍生物和含有它们的药物组合物的方法。
    • 5. 发明申请
    • Indol-2-amides as glycogen phosphorylase inhibitors
    • 吲哚-2-酰胺作为糖原磷酸化酶抑制剂
    • US20060199966A1
    • 2006-09-07
    • US10567798
    • 2004-08-18
    • Stuart Norman BennettIain SimpsonPaul Robert Owen Whittamore
    • Stuart Norman BennettIain SimpsonPaul Robert Owen Whittamore
    • C07D293/00
    • C07D405/12C07D209/42
    • A compound of the formula (1) or a pharmaceutically-acceptable salt, or pro-drug thereof; (1) wherein, for example, R4 is halo or (1-4C)alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; m is 0, 1 or 2; R1 is halo, cyano or carboxy; R2 is for example methyl; R3 is for example selected from halo(1-4C)alkyl, dihalo(1-4C)alkyl, trifluoromethyl, hydroxy(1-4C)alkyl, dihydroxy(2-4C)alkyl, trihydroxy(3-4C)alkyl, cyano(1-4C)alkyl (optionally substituted on alkyl with hydroxy), (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkoxy(1-4C)alkyl, di[(1-4C)alkoxy](1-4C)alkyl, (hydroxy)[(1-4C)alkoxy](1-4C)alkyl; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of compounds and pharmaceutical compositions containing them are described.
    • 式(1)的化合物或其药学上可接受的盐或其前药; (1)其中例如R 4为卤素或(1-4C)烷基; A是亚苯基或亚杂芳基; n为0,1或2; m为0,1或2; R 1是卤素,氰基或羧基; R 2是例如甲基; R 3是例如选自卤代(1-4C)烷基,二卤代(1-4C)烷基,三氟甲基,羟基(1-4C)烷基,二羟基(2-4C)烷基,三羟基( (1-4C)烷基,(1-4C)烷氧基(1-4C)烷氧基(1-4C)烷氧基(1-4C)烷氧基(1-4C) (1-4C)烷氧基](1-4C)烷基,(羟基)[(1-4C)烷氧基](1-4C)烷基; 具有糖原磷酸化酶抑制活性,因此具有与增加的糖原磷酸化酶活性相关的疾病状态的治疗价值。 描述了制备含有它们的化合物和药物组合物的方法。
    • 8. 发明授权
    • Heterocyclic derivatives
    • US5919793A
    • 1999-07-06
    • US537827
    • 1995-10-26
    • George Robert BrownPaul Robert Owen WhittamoreDavid Robert Brittain
    • George Robert BrownPaul Robert Owen WhittamoreDavid Robert Brittain
    • A61K31/435A61P3/06A61P9/10C07D453/02C07D435/02
    • C07D453/02
    • Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.2 -- (wherein n is 0, 1 or 2); Ar is phenyl which bears one or more substituents independently selected from the groups (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, (1-6C)alkoxycarbonyl(1-6C)alkyl, (1-6C)alkoxy(1-6C)alkyl, (1-6C)alkylamino, di-�(1-6C)alkyl!amino, carbamoyl, (1-6C) alkylcarbamoyl, di-�(1-6C)alkyl!carbamoyl, (1-6C)alkenyl and oxime derivatives thereof and O--(1-6C)alkyl ethers of said oximes (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl when substituted by one or more groups selected from (1-6C)alkoxycarbonyl, (1-6C)alkanoyl and oxime derivatives thereof and O-(1-6C)alkyl ethers of said oxime derivatives, (1-6C)alkanoylamimo, (1-6C)alkanoyloxy, (1-6C)alkanoyloxy(1-6)alkyl, carbamoyl, N-(1-6C)alkylcarbamoyl, N,N-di�(1-6C)alkyl!carbamoyl, amino, (1-6C)alkylamino, di-�(1-6C)alkyl!amino, (1-6C)alkoxy, (2-6C)alkenyloxy, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl (2-6C)alkenyl, (2-6C)alkynyl, phenyl, phenoxy, cyano, nitro, hydroxy and carboxy; and wherein Ar may bear further substituents; and their pharmaceutically acceptable salts inhibit squalene synthese and are hence useful in lowering cholesterol levels in blood plasma Processes for preparing compounds of formula (I) are also referred to as well as pharmaceutical compositions containing them and their use in medicine.